Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate-Reference-Cited by-同舟云学术

Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate

Published:2014-01-16 Issue:2 Volume:55 Page:183-190
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Ezziddin Samer,Attassi Mared,Yong-Hing Charlotte J.,Ahmadzadehfar Hojjat,Willinek Winfried,Grünwald Frank,Guhlke Stefan,Biersack Hans-Jürgen,Sabet Amir

Publisher

Society of Nuclear Medicine

Subject

Radiology Nuclear Medicine and imaging

Reference46 articles.

1. Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors

2. Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

3. Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers

4. Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate

5. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy

Cited by 165 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Head-to-head comparison of contrast-enhanced CT, dual-layer spectral-detector CT, and Gd-EOB-DTPA-enhanced MR in detecting neuroendocrine tumor liver metastases;European Journal of Radiology;2024-12

2. Retrospective evaluation of the predictive value of tumour burden at baseline [68 Ga]Ga-DOTA-TOC or -TATE PET/CT and tumour dosimetry in GEP-NET patients treated with PRRT;EJNMMI Reports;2024-08-08

3. Trans-arterial embolization versus chemoembolization for neuroendocrine liver metastases: a propensity matched analysis;HPB;2024-08

4. Subgrading of G2 Pancreatic Neuroendocrine Tumors as 2A (Ki67 3% to < 10%) Versus 2B (10% to ≤ 20%) Identifies Behaviorally Distinct Subsets in Keeping with the Evolving Management Protocols;Annals of Surgical Oncology;2024-07-02

5. Intra-arterial PRRT with Lu-177 DOTATATE in Liver-dominant Metastatic Neuroendocrine Tumors: Early Assessment of Efficacy and Toxicity;Indian Journal of Nuclear Medicine;2024-03